The first round of voting in OncMadness 2020 is over. Let’s check out where things stand and see if you’re on track to match the Blue Ribbon Panel’s choices.
REGION 1: Classical Chemotherapy
TAILORx versus Early HER2+ breast cancer escalation/de-escalation strategies
And the winner is: TAILORx
Here’s what our Blue Ribbon Panel had to say:
“Theoretically more impactful.”
“It’s the way forward.”
“Practice-changing advance.”
Gentler therapy for geriatric patients versus Oral chemo in AML
And the winner is: Gentler therapy for geriatric patients
Here’s what our Blue Ribbon Panel had to say:
“Profound implications for quality of life and for economics.”
REGION 2: Supportive Care
Constipation prevention versus Constipation treatment
And the winner is: Constipation prevention
Here’s what our Blue Ribbon Panel had to say:
“It’s the future of pain management.”
“Important to explore non-pharmacologic interventions.”
Opioid analgesics for cancer pain versus Co-analgesics for cancer pain
And the winner is: Co-analgesics for cancer pain
Here’s what our Blue Ribbon Panel had to say:
“Given the opioid crisis, this seems critical.”
“Important for avoiding opioid dependence.”
REGION 3: Immunotherapy & Cellular Therapy
Checkpoint inhibition in metastatic NSCLC versus Immunotherapy in GU cancers
And the winner is: Checkpoint inhibition in metastatic NSCLC
Here’s what our Blue Ribbon Panel had to say:
“Both are important. Hard choice. Lung cancer is more common.”
“Major reason for declining mortality in cancer 2020.”
“Major impact in the right patients.”
‘Off the shelf’ cellular Tx in blood cancers versus CAR-T in hematologic malignancies
And the winner is: CAR-T in hematologic malignancies
REGION 4: Patient-Reported Outcomes
Treatment adherence issues versus Real-world data and evidence
And the winner is: Real-world data and evidence
Here’s what our Blue Ribbon Panel had to say:
“The answers will be in the data.”
“More timely issue. We haven’t been able to deal with fragmentation for years. RWE may help there too.”
Care fragmentation versus Geriatric risk assessment
And the winner is: Care fragmentation
Here’s what our Blue Ribbon Panel had to say:
“More important than ever to be connected.”
“Care fragmentation remains an important issue.”
REGION 5: Health Policy
Use of clinical pathways versus ACA Medicaid expansion
And the winner is: Use of clinical pathways
Here’s what our Blue Ribbon Panel had to say:
“Clinically oriented is what is needed to advance medicine.”
“Price matters.”
Price of new therapies versus FDA shortcuts
And the winner is: Price of new therapies
Here’s what our Blue Ribbon Panel had to say:
“This is the key to all of these new therapies which are pushed hard by industry and appear effective.”
REGION 6: Precision Therapy and Targeted Agents
BEACON and RAS targeting in colorectal cancer versus PARP inhibitors in BRCA-mutated tumors
And the winner is: BEACON and RAS targeting in colorectal cancer
Here’s what our Blue Ribbon Panel had to say:
“RAS is the holy grail.”
“Broad implications for many tumor types.”
CDK4/6 inhibitors in metastatic breast cancer versus Novel antiandrogens in prostate cancer
And the winner is: CDK4/6 inhibitors in metastatic breast cancer
Here’s what our Blue Ribbon Panel had to say:
“Big impact, large population.”
REGION 7: Role of Local Therapy (i.e., Surgery/Radiation)
.jpg)
Pre-op CRT in pancreatic cancer versus Local approaches for oligometastatic disease
And the winner is: Local approaches for oligometastatic disease
Here’s what our Blue Ribbon Panel had to say:
“Applicable to more cancers. Growing topic.”
Reducing radiation in DLBCL versus De-escalation in HPV-positive oropharyngeal cancers
And the winner is: De-escalation in HPV-positive oropharyngeal cancers
Here’s what our Blue Ribbon Panel had to say:
“Epidemiologically a bigger problem.”
“A cool biologic precept. Both are promissory notes.”
“On the rise in the USA.”
REGION 8: Screening and Risk Reduction
Prostate cancer screening versus Colorectal cancer screening
And the winner is: Colorectal cancer screening
Here’s what our Blue Ribbon Panel had to say:
“A major way to reduce mortality.”
Colorectal cancer screening has a “known impact.”
Cancer prevention versus Early detection
And the winner is: Early detection
Here’s what our Blue Ribbon Panel had to say:
“Science rapidly evolving.”
“Broader topic.”
Source: MedicalNewsToday.com
